| 1.245 -0.035 (-2.73%) | 07-16 11:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.68 | 1-year : | 1.96 |
| Resists | First : | 1.44 | Second : | 1.68 |
| Pivot price | 1.19 |
|||
| Supports | First : | 1.15 |
Second : | 0.98 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.17 |
| MA(100) : | 3.06 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 57.1 |
D(3) : | 57.7 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 4.98 | Low : | 0.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADCT ] has closed below upper band by 38.8%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.31 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Tue, 30 Jun 2026
ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma - Stock Titan
Sat, 27 Jun 2026
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views - Yahoo Finance
Wed, 24 Jun 2026
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details - Yahoo Finance
Wed, 24 Jun 2026
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities - PR Newswire
Mon, 08 Jun 2026
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL - Slideshow - Seeking Alpha
Thu, 04 Jun 2026
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 14.4 (%) |
| Held by Institutions | 67.8 (%) |
| Shares Short | 5,990 (K) |
| Shares Short P.Month | 6,070 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.71 |
| Profit Margin | -173.1 % |
| Operating Margin | -121.1 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -9.5 % |
| Gross Profit (p.s.) | -0.17 |
| Sales Per Share | 0.62 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -1.29 |
| PEG Ratio | 0 |
| Price to Book value | -0.74 |
| Price to Sales | 2 |
| Price to Cash Flow | -1.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|